Suppliers and packagers for generic pharmaceutical drug: resmetirom

resmetirom

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Madrigal	REZDIFFRA	resmetirom	TABLET;ORAL	217785	NDA	Madrigal Pharmaceuticals, Inc.	82576-060-30	30 TABLET, COATED in 1 BOTTLE (82576-060-30)	2024-03-14
Madrigal	REZDIFFRA	resmetirom	TABLET;ORAL	217785	NDA	Madrigal Pharmaceuticals, Inc.	82576-080-30	30 TABLET, COATED in 1 BOTTLE (82576-080-30)	2024-03-14
Madrigal	REZDIFFRA	resmetirom	TABLET;ORAL	217785	NDA	Madrigal Pharmaceuticals, Inc.	82576-080-90	90 TABLET, COATED in 1 BOTTLE (82576-080-90)	2024-03-14

RESMETIROM Drug Supply Chain Analysis

Last updated: February 19, 2026

Resmetirom, a thyroid hormone receptor-beta (TRβ) selective agonist, is under development for the treatment of nonalcoholic steatohepatitis (NASH) with liver fibrosis. Key suppliers for its development and potential commercialization are critical for ensuring consistent production and market availability. This analysis identifies and profiles significant entities involved in the Resmetirom supply chain, focusing on active pharmaceutical ingredient (API) manufacturing, formulation, and specialized contract manufacturing.

Who are the Key API Manufacturers for Resmetirom?

The primary active pharmaceutical ingredient (API) for Resmetirom is synthesized through complex chemical processes. Identifying the specific contract manufacturing organizations (CMOs) responsible for its large-scale production is vital for supply chain security. While specific contractual relationships are often proprietary, general industry trends and publicly available information point to established API manufacturers with expertise in complex organic synthesis.

Primary API Synthesis Partners

Based on industry prevalence for novel small molecule APIs and Medtronic's (the developer's) typical outsourcing strategies for such complex molecules, the following types of CMOs are likely involved or will be critical partners:

• Large-Scale API Manufacturers with Advanced Chemistry Capabilities: These companies possess the infrastructure and regulatory compliance (cGMP) to produce APIs in metric ton quantities. They typically handle multi-step syntheses requiring specialized equipment and expertise.
• Specialty Chemical Suppliers: For certain advanced intermediates or unique reagents required in the Resmetirom synthesis, specialized chemical companies may be engaged. These suppliers focus on niche areas of organic chemistry or the production of high-purity compounds.
• Early-Stage Development CMOs: During clinical development, smaller, more agile CMOs often handle initial API production. As the drug advances, manufacturing is typically transferred to larger, more established facilities capable of commercial scale.

Example Profile of a Potential API Partner Type:

• Lonza: A global leader in pharmaceutical contract development and manufacturing, Lonza has extensive experience in complex small molecule synthesis and large-scale API production. They operate cGMP facilities globally and have a strong track record in supporting drug commercialization from early development through to market supply. Their expertise in process optimization and scale-up makes them a logical candidate for critical API manufacturing.
• Catalent: Another major player in the pharmaceutical outsourcing sector, Catalent offers integrated solutions from API development to finished dosage forms. Their API manufacturing capabilities include advanced chemical synthesis and large-scale production, adhering to strict quality standards.

Data Points:

• API synthesis often involves 5-15 distinct chemical steps for novel small molecules.
• cGMP compliance requires rigorous documentation, quality control, and facility audits.
• Commercial API production can range from 100 kg to several metric tons annually, depending on drug dosage and patient population.

What are the Key Formulation and Finished Dosage Form (FDF) Manufacturers?

Once the Resmetirom API is produced, it must be formulated into a finished dosage form, typically oral capsules or tablets, for patient administration. This stage requires specialized expertise in pharmaceutical formulation, manufacturing, and packaging.

Formulation and FDF Production Partners

• Contract Development and Manufacturing Organizations (CDMOs) with Solid Oral Dosage Capabilities: These organizations specialize in taking APIs and transforming them into finished drug products. They manage processes such as milling, blending, granulation, encapsulation or tableting, coating, and packaging.
• Excipient Suppliers: Inert substances used in drug formulations to aid manufacturing or improve stability, bioavailability, or patient acceptance. Key excipients for oral solid dosage forms include fillers (e.g., microcrystalline cellulose), binders (e.g., povidone), disintegrants (e.g., croscarmellose sodium), and lubricants (e.g., magnesium stearate).

Example Profile of a Potential FDF Partner Type:

• Thermo Fisher Scientific (Patheon): A leading CDMO with a global network of facilities offering comprehensive drug product manufacturing services. Patheon's expertise in solid oral dosage forms, including complex formulations and high-potency compounds, positions them as a strong candidate for Resmetirom FDF production.
• Evonik Industries: A specialty chemicals company that is also a significant supplier of high-quality pharmaceutical excipients. They provide a range of functional ingredients crucial for tablet and capsule formulations, impacting drug release profiles and stability.

Data Points:

• Typical capsule fill weights for oral medications range from 200 mg to 500 mg.
• Formulation development aims to ensure consistent drug release and bioavailability.
• Packaging operations for commercial products include blister packs or bottles, with serialization for track-and-trace.

What are the Regulatory and Quality Assurance Requirements for Suppliers?

Suppliers of pharmaceuticals, especially for novel therapeutics like Resmetirom, must adhere to stringent regulatory standards to ensure product safety, efficacy, and quality.

Key Regulatory and QA Considerations

• Current Good Manufacturing Practices (cGMP): Mandated by regulatory agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). cGMP regulations cover all aspects of manufacturing, from raw materials and facilities to personnel training and quality control.
• ICH Guidelines: The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use provides global standards for drug development and manufacturing quality. Key guidelines include ICH Q7 (Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients) and ICH Q10 (Pharmaceutical Quality System).
• Supplier Audits and Qualification: Pharmaceutical companies conduct rigorous audits of their suppliers to ensure compliance with cGMP and other quality standards. This includes assessing manufacturing processes, quality systems, analytical capabilities, and regulatory history.
• Drug Master Files (DMFs): Manufacturers of APIs often submit DMFs to regulatory agencies. These confidential documents contain detailed information about the chemistry, manufacturing, and controls of the API. The drug sponsor can then reference the DMF in their regulatory submissions.

Data Points:

• FDA inspections occur annually or biennially for active manufacturing sites.
• A Quality Agreement is established between the drug sponsor and each supplier to delineate responsibilities for quality control and regulatory compliance.
• Deviations from cGMP can lead to regulatory actions, including warning letters, import alerts, and product recalls.

Who are the Potential Key Raw Material and Intermediate Suppliers?

The synthesis of Resmetirom, like most complex small molecules, relies on a specific set of starting materials and advanced intermediates. The reliable sourcing of these components is fundamental to uninterrupted manufacturing.

Raw Material and Intermediate Sourcing

• Fine Chemical Manufacturers: Companies specializing in producing high-purity organic chemicals that serve as building blocks for more complex molecules.
• Custom Synthesis Providers: Firms that can produce proprietary or hard-to-find chemical intermediates on a contractual basis.
• Global Chemical Distributors: Companies that manage the supply chain for a wide range of chemical reagents and solvents.

Data Points:

• The supply chain for complex intermediates can involve multiple global sourcing locations.
• Lead times for custom-synthesized intermediates can range from 8 to 24 weeks.
• A robust risk management strategy includes qualifying secondary suppliers for critical raw materials.

What are the Strategic Implications of the Resmetirom Supply Chain?

Understanding the supplier landscape for Resmetirom has significant implications for Medtronic and potential investors. It informs risk assessment, cost projections, and market entry strategies.

Strategic Considerations

• Supply Chain Redundancy: Establishing multiple qualified suppliers for critical components (API, key intermediates, excipients) mitigates risks associated with single-source dependencies, geopolitical instability, or manufacturing disruptions.
• Cost of Goods Sold (COGS): The efficiency and scale of API and FDF manufacturing directly impact the COGS. Negotiating favorable terms with CMOs and optimizing synthetic routes are crucial for profitability.
• Intellectual Property Protection: Ensuring that all suppliers adhere to strict confidentiality agreements and intellectual property (IP) protection protocols is paramount, especially during the drug's development and patent-protected lifecycle.
• Geographic Diversification: Sourcing from multiple geographic regions can reduce risks related to trade disputes, natural disasters, and localized regulatory changes.

Data Points:

• API manufacturing costs can represent 20-40% of the total COGS for a small molecule drug.
• Supply chain disruptions can delay clinical trials and commercial launches, incurring significant financial losses.
• The duration of patent exclusivity for Resmetirom will influence the long-term strategic importance of these supplier relationships.

Key Takeaways

• The Resmetirom supply chain involves specialized API manufacturers for complex synthesis and CDMOs for finished dosage form production.
• Regulatory compliance, particularly cGMP, is a non-negotiable requirement for all key suppliers.
• Sourcing of raw materials and critical intermediates requires careful qualification and risk management.
• Supply chain redundancy, cost optimization, and IP protection are critical strategic considerations for Medtronic.

Frequently Asked Questions

1. What is the estimated commercial manufacturing scale for Resmetirom? Commercial manufacturing scale depends on the projected patient population and dosage regimen. For NASH indications, this can range from hundreds of kilograms to multiple metric tons of API annually, requiring significant FDF production capacity.
2. Are there any publicly disclosed partnerships for Resmetirom manufacturing? Specific manufacturing partnerships for drugs in development are often confidential until commercialization or public disclosure by the sponsoring company. Investors and analysts typically infer potential partners based on industry capabilities and historical outsourcing practices.
3. What are the primary risks associated with the Resmetirom supply chain? Key risks include single-source dependencies for critical materials, manufacturing process failures leading to quality deviations, geopolitical disruptions impacting global supply, and potential IP infringement by third parties.
4. How does the patent status of Resmetirom influence its supply chain strategy? During the patent-protected period, the focus is on securing a stable, high-quality supply for commercial launch. Post-patent expiry, generic manufacturers will seek alternative suppliers, increasing competition and potentially driving down manufacturing costs.
5. What are the typical timelines for qualifying a new pharmaceutical supplier for API or FDF manufacturing? Supplier qualification typically involves extensive technical assessments, quality audits, validation of manufacturing processes, and regulatory review, which can take between 6 to 18 months.

Cited Sources

1. U.S. Food and Drug Administration. (n.d.). Current Good Manufacturing Practice (CGMP) Regulations. Retrieved from [FDA Website]
2. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Guidelines. Retrieved from [ICH Website]
3. Lonza Group AG. (n.d.). Drug Substance Manufacturing. Retrieved from [Lonza Website]
4. Catalent, Inc. (n.d.). Active Pharmaceutical Ingredients (APIs). Retrieved from [Catalent Website]
5. Thermo Fisher Scientific Inc. (n.d.). Contract Development and Manufacturing Services. Retrieved from [Thermo Fisher Scientific Website]
6. Evonik Industries AG. (n.d.). Pharmaceutical Excipients. Retrieved from [Evonik Website]